Background: Human natural antibodies have been found that owe their candidacidal action to the mimicry of a yeast killer toxin produced by the yeast Pichia anomala (PaKT). Candidacidal human natural antibodies (KTAb) are elicited by and bind to a KT receptor (PaKTR) present on the cell surface of infectious PaKT-sensitive microorganisms. Because of the recognized susceptibility of Pneumocystis carinii organisms to PaKT upon the occurrence of specific PaKTR, we examined whether human natural KTAb could also bind to and inhibit P. carinii. Materials and Methods: Immunoaffinity-purified KTAb from the vaginal fluid of patients affected by candidiasis were tested and compared with PaKT for their ability to inhibit rat-derived P. carinii attachment to epithelial lung cells as well as infectivity to nude rats. Immunofluorescence studies were also performed by biotinylated PaKT in competition with human KTAb to establish their specific binding to PaKTR on the surface of rat-derived and human P. carinii organisms.
INTRODUCTION
Although the development of new therapeutic strategies against pneumocystosis remains a priority, few drugs capable of inhibiting specifically the growth of Pneumocystis carinii without secondary effects are known (1) . During the last few years, the susceptibility of mouse-or rat-derived P. carinii to a Pichia anomala candidacidal killer toxin (PaKT) has been demonstrated by using in vitro attachment tests or infectivity assays (2) (3) (4) . However, the PaKT, which is toxic and antigenic, other than inactive under human physiological conditions, could not be used as a systemic antibiotic (5, 6) . For this reason, a new strategy to 545 control candidiasis or pneumocystosis was developed by using yeast killer toxin-like anti-idiotypic antibodies (KT-IdAb) (6, 7) . An immunoglobulin GI (IgGI) monoclonal antibody (MAbKT4) that neutralized in vitro the fungicidal activity of PaKT was used as an immunogen (idiotypic vaccination) to elicit KT-IdAb capable of inhibiting in vitro the growth of PaKT-sensitive Candida albicans (8) (9) (10) (11) . KT-IdAb raised in sera and vaginal secretions of mice and rats through parenteral and intravaginal immunization with MAbKT4 were able to confer immunoprotection against systemic or mucosal experimental candidiasis (9, 10) . Presumably, the paratope of MAbKT4 has regions that are similar to those of the yeast killer toxin receptor (PaKTR) at the surface of sensitive target microbial cells. Thus, KT-IdAb reactive with the MAbKT4 idiotype could also react with the PaKTR at the surface of C. albicans or P. carinii cells (2, 12) . The immune system therefore should recognize the PaKTR of infectious microorganisms such as the MAbKT4 idiotype, and consequently, anti-receptor yeast killer toxinlike antibodies (KTAb) should be part of the antibody repertoire of animals experimentally infected with PaKTR-bearing microorganisms or of patients affected by candidiasis. Anti-receptor KTAb have been elicited and detected in animals never immunized with MAbKT4 but repeatedly infected with PaKT-sensitive C. albicans cells ( 13) . Likewise, human natural KTAb prevalently of the IgA isotype were found in the vaginal secretions of patients affected by vaginal candidiasis (13) . MAbKT4-affinity chromatography-purified human KTAb proved to be as candidacidal in vitro as those KT-IdAb raised in rat vaginas by idiotypic vaccination with MAbKT4 (10). The antifungal activity of human KTAb was totally neutralized by previous reaction with MAbKT4, confirming the high specificity of their killer effect. Human natural purified KTAb were also capable of transferring passive immunity to naive animals experimentally infected with PaKTRbearing C. albicans cells (13) . Human natural KTAb were shown to interact with specific Pa-KTR of C. albicans cells by competition experiments with PaKT in immunofluorescence assays. (14) .
In this study, the anti-P. carinii activity of human natural candidacidal KTAb was evaluated. They were tested for their ability to 24 hr in an atmosphere of 5% CO2 at 37°C. After incubation, the coverslips were washed three times with phosphate buffer at 370C to eliminate unattached and dead parasites. Each experiment was performed in triplicate. Attached P. carinii organisms were microscopically detected using methanol-Giemsa and counted by a previously described method (2, 16) .
Nude Rat Model Male and female nude (nu/nu) rats 8 weeks of age were used as recipient animals. These animals came from a colony (Pasteur Institute of Lille, France) previously used in several P. carinii transmission experiments which had been found to be free of latent P. carinii infection. They were immunosuppressed for 15 days with corticosteroid (dexamethasone; Merck Sharp and Dohme, France) in their drinking water (1 mg/i). Under corticosteroid administration, the parasite number showed low interindividual or intersexual variation. Nude rats were anesthetized with a drug cocktail given intraperitoneally (17) . They were inoculated by the intratracheal route with 10 X 107 parasites/ 100 ,lI of medium along with 0.3 ml of air. In these inocula, the cysts' percentage by comparison with trophozoites was 4-7%. The tracheal wound was closed with nonresorbable sutures (3/8 Seracap, Serquighy, France). All manipulations were carried out under sterile conditions and the hooded rat cages were placed in sterile boxes maintained under sterile air-flow (Esi Flufrance, Wissous, France). The cages, food, water, and bedding were sterilized before being used.
Evaluation of P. carinii Infectivity in Nude Rats
The experimental animal model of nude rats was used at first to control that P. carinii infectivity was affected by the antibiotic activity of PaKT. For this evaluation, five independent experiments were performed with four groups of four animals each. Samples of freshly extracted P. carinii organisms were incubated for 90 min at 25°C in 500 ,ul of the following reagents before being inoculated into the animals: DMEM, pH 7.2; PaKT, pH 4.6 (active killer toxin); PaKT, pH 7 The immunofluorescence studies were carried out with rat-derived and human P. carinii organisms obtained from experimental animals and bronchial washings of patients affected by pneumocystosis by using biotinylated PaKT in competition with human natural KTAb according to a procedure previously described (18, 19) . Briefly, concentrated PaKT (8 mg/ml) was dialyzed against 500 ml of labeling buffer (0.1 M NaHCO3, 0.1 M NaCl adjusted to pH 7.4 with concentrated HCI) at 40C with three changes over 2 days. After dialysis, 30 (Fig. 3) .
Visualization of PaKTR in P. carinii Immunofluorescence studies carried out by using biotinylated PaKT permitted visualization of the putative KTR in rat-derived and human P. carinii organisms (Fig. 4) . The immunofluorescence reactivity was lost by the competition of human natural KTAb against PaKT for binding to the surface of P. carinii organisms of both animal and human origin.
DISCUSSION
P. carinii is an opportunistic microorganism recently reclassified in the kingdom Fungi on the basis of nucleic acid analysis (20) (21) (22) (23) (24) . In immunocompetent hosts, P. carinii infection generally stimulates cell-mediated and antibody immunity. There is strong evidence that both of these types of immune responses are important for the control of infections. The precise role of humoral immunity, however, remains to be clarified (25) (26) (27) (28) . In the cell wall of P. carinii, the presence of yeast glucan has been revealed (29) . This represents one the major constituents of cell wall receptors for some yeast killer toxins such as that of P. anomala, which displays a large spectrum of antimicrobial activity against many pathogenic microorganisms, including C. albicans, a common opportunistic pathogen in HIV patients (30) (31) (32) . In previous studies, we demonstrated that a candidacidal P. anomala killer toxin (PaKT) was also able to inhibit the in vitro attachment of rat-derived P. carinii (2) or its in vivo infectivity (3) . These antimicrobial activities have proven to be highly specific because they can be abolished by prior adsorption of PaKT with a neutralizing monoclonal antibody (MAbKT4) that also allows the immunofluorescence detection of specific PaKTR on the cell wall of P. carinii organisms treated with PaKT (2). MAbKT4 has been extensively used to vaccinate mice and rats by parenteral or mucosal administration against experimental intravenous and intravaginal infections with PaKT-sensitive C. albicans cells (idiotypic vaccination) (9, 10 (13) . The goal of this study was to verify if such natural candidacidal antibodies representing the internal image of PaKT could also display activity against recognized PaKT-sensitive P. carinii organisms, even though the study was not designed to draw definitive conclusions about the relationship of antibody concentration to killer effect. We have shown that human natural candidacidal KCTAb were able to inhibit the in vitro attachment of rat-derived P. carinii organisms to epithelial lung cells as well as parasite infectivity in the nude rat model (16) . Data obtained from the in vitro attachment assay showed that 55.5% of the human natural KTAb-treated parasites were not attached to WI38 VA13 cells. The same effect had been observed by using PaKT-treated parasites in other cell line systems (2,3). Human natural KTAb were shown to display an inhibitory activity comparable to that of PaKT (16) . Data obtained with the nude rat model confirmed this finding by showing inhibition of the infectivity of P. carinii organisms treated with KTAb as well as with PaKT. Moreover, when human KTAb were adsorbed with mAbKT4, the inhibitory effect on the attachment of parasite and infectivity was significantly neutralized (p < 0.001). These data suggest that KTAb, representing the internal image of PaKT, were able to interact with the idiotype of PaKT-neutralizing MAbKT4, thus attesting to the specificity of their antibiotic activity.
As marked differences related to host species were reported among P. carinii strains (33, 34) , it could be argued that the results are only applicable to rat-derived P. carinii isolates. However, we have previously shown that PaKT is also active against mouse-derived P. carinii (4). Moreover, PaKT or KTAb are equally active against C. albicans, which suggests that the killer activity of these compounds is dependent on transphyletic receptors (14) . The putative PaKTR on C. albicans and P. carinii, which were cytochemically located by using polyclonal rabbit KT-IdAb or PaKT and MAbKT4 with indirect immunofluorescence assays (2, 12) , were also visualized either in ratderived or human P. carinii organisms by using biotinylated PaKT in the direct immunofluorescence procedure. The competition exerted by KTAb to PaKT, particularly in the human clinical samples, proved that despite the animal origin of parasite, these antibodies bind to the same Pa-KTR of P. carinii as PaKT.
Although our experiments demonstrated the ability of KTAb to inhibit rat-derived parasite in vitro attachment and in vivo infectivity to the nude rat, these observations did not indicate whether trophozoites were less or more affected than the cystic forms by the killer effect. Further experiments are needed to evaluate the sensitivity of the different life stages of P. carinii to PaKT or PaKT-like antibodies.
Our findings suggest that humoral immunity could play a potential role in the control of P. carinii infection because PaKT-like anti-receptor antibodies are elicited through immunization by specific PaKTR of infectious microorganisms acting as antigens (14) . The validation of KT-like antibodies, moreover, could lead to the cloning of genes from human lymphocytes of selected donors that encode for KTAb-variable regions, thus obtaining Fab characterized by antibiotic activity that could be most properly used as immunotherapeutants in the treatment of pneumocystosis. The potential therapeutic effect of murine yeast killer toxin-like monoclonal and single-chain recombinant antibodies previously described in an experimental model of candidal vaginitis strongly supports this expectation (18, 19) .
Further studies using properly engineered MAbKT4 idiotype-like vaccines will be required to extend the prophylactic value of idiotypic vaccination against experimental pneumocystosis to ascertain if it could be used in individuals at risk of developing the disease.
